Jeffrey M. Besterman
Corporate Officer/Principal at National Cancer Institute
Profile
Jeffrey M.
Besterman is currently a Member-Special Review Committee at the National Cancer Institute.
Previously, he worked as the CSO and Executive VP-Research & Development at Mirati Therapeutics, Inc. from 2012 to 2013.
He also worked as the Head-Cell Biology Department at GlaxoSmithKline Research & Development.
Besterman holds a doctorate degree from the University of Vermont and an undergraduate degree from The State University of New York.
Jeffrey M. Besterman active positions
| Companies | Position | Start |
|---|---|---|
National Cancer Institute
 National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Corporate Officer/Principal | - |
Former positions of Jeffrey M. Besterman
| Companies | Position | End |
|---|---|---|
| MIRATI THERAPEUTICS | Chief Tech/Sci/R&D Officer | 2013-03-13 |
GlaxoSmithKline Research & Development
 GlaxoSmithKline Research & Development Pharmaceuticals: MajorHealth Technology GlaxoSmithKline Research & Development manufactures pharmaceutical products. It has locations in the U.S. and across Europe. The company has treatments in the works for therapies such as infectious diseases, neuroscientific requirements and respiratory needs. GlaxoSmithKline is located in Research Triangle Park, NC | Corporate Officer/Principal | - |
Training of Jeffrey M. Besterman
| The State University of New York | Undergraduate Degree |
| University of Vermont | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
National Cancer Institute
National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Miscellaneous |
GlaxoSmithKline Research & Development
GlaxoSmithKline Research & Development Pharmaceuticals: MajorHealth Technology GlaxoSmithKline Research & Development manufactures pharmaceutical products. It has locations in the U.S. and across Europe. The company has treatments in the works for therapies such as infectious diseases, neuroscientific requirements and respiratory needs. GlaxoSmithKline is located in Research Triangle Park, NC | Health Technology |
- Stock Market
- Insiders
- Jeffrey M. Besterman
